Liberum Capital restated their hold rating on shares of AstraZeneca plc (LON:AZN) in a research note published on Wednesday. They currently have a GBX 5,000 ($65.98) price target on the biopharmaceutical company’s stock.
Several other research analysts have also weighed in on AZN. J P Morgan Chase & Co set a GBX 4,200 ($55.42) price objective on shares of AstraZeneca plc and gave the stock a neutral rating in a research note on Wednesday, August 9th. Barclays PLC restated an overweight rating and set a GBX 5,500 ($72.58) price objective on shares of AstraZeneca plc in a research note on Monday, August 7th. Shore Capital restated a hold rating on shares of AstraZeneca plc in a research note on Tuesday, October 31st. Jefferies Group LLC lowered their price objective on shares of AstraZeneca plc from GBX 4,900 ($64.66) to GBX 4,400 ($58.06) and set a hold rating on the stock in a research note on Tuesday, August 1st. Finally, Investec upgraded shares of AstraZeneca plc from a hold rating to a buy rating and lowered their price objective for the stock from GBX 5,000 ($65.98) to GBX 4,900 ($64.66) in a research note on Wednesday, August 9th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the company. The company has a consensus rating of Hold and an average target price of GBX 5,183.55 ($68.40).
AstraZeneca plc (AZN) opened at GBX 5,157.64 ($68.06) on Wednesday. AstraZeneca plc has a 52 week low of GBX 3,996 ($52.73) and a 52 week high of GBX 5,520 ($72.84).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
What are top analysts saying about AstraZeneca plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AstraZeneca plc and related companies.